207 related articles for article (PubMed ID: 33367811)
21. The Association of Obesity and Microvascular Complications with Glycemic Control in Patients with Type 2 Diabetes Mellitus.
Bijelic R; Balaban J; Milicevic S; Sipka SU
Med Arch; 2020 Feb; 74(1):14-18. PubMed ID: 32317828
[TBL] [Abstract][Full Text] [Related]
22. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino F; Home PD; Tuomilehto J
Diabetes Care; 2016 Aug; 39 Suppl 2():S187-95. PubMed ID: 27440832
[TBL] [Abstract][Full Text] [Related]
23. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
24. Variability of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes.
Pai YW; Lin CH; Lee IT; Chang MH
Diabetes Metab; 2018 Mar; 44(2):129-134. PubMed ID: 29459007
[TBL] [Abstract][Full Text] [Related]
25. Glycemic variability evaluated by HbA1c rather than fasting plasma glucose is associated with adverse cardiovascular events.
Sheng L; Yang G; Chai X; Zhou Y; Sun X; Xing Z
Front Endocrinol (Lausanne); 2024; 15():1323571. PubMed ID: 38419951
[TBL] [Abstract][Full Text] [Related]
26. Mean and visit-to-visit variability of glycemia and left ventricular diastolic dysfunction: A longitudinal analysis of 3025 adults with serial echocardiography.
Ahn J; Koh J; Kim D; Kim G; Hur KY; Seo SW; Kim K; Kim JH; Yang JH; Jin SM
Metabolism; 2021 Mar; 116():154451. PubMed ID: 33248066
[TBL] [Abstract][Full Text] [Related]
27. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
[TBL] [Abstract][Full Text] [Related]
28. Visit-to-Visit Variability of Fasting Plasma Glucose and the Risk of Cardiovascular Disease and All-Cause Mortality in the General Population.
Wang A; Liu X; Xu J; Han X; Su Z; Chen S; Zhang N; Wu S; Wang Y; Wang Y
J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29187392
[TBL] [Abstract][Full Text] [Related]
29. An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Konig M; Lamos EM; Stein SA; Davis SN
Curr Diabetes Rev; 2013 Sep; 9(5):371-81. PubMed ID: 23865412
[TBL] [Abstract][Full Text] [Related]
30. Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes.
Yang CP; Lin CC; Li CI; Liu CS; Lin CH; Hwang KL; Yang SY; Li TC
Cardiovasc Diabetol; 2020 Jan; 19(1):4. PubMed ID: 31910828
[TBL] [Abstract][Full Text] [Related]
31. Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial.
Segar MW; Patel KV; Vaduganathan M; Caughey MC; Butler J; Fonarow GC; Grodin JL; McGuire DK; Pandey A
Diabetes Care; 2020 Aug; 43(8):1920-1928. PubMed ID: 32540922
[TBL] [Abstract][Full Text] [Related]
32. Metabolic memory: Evolving concepts.
Misra A; Bloomgarden Z
J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
[TBL] [Abstract][Full Text] [Related]
33. Implications of fasting plasma glucose variability on the risk of incident peripheral artery disease in a population without diabetes: a nationwide population-based cohort study.
Chung HS; Hwang SY; Kim JA; Roh E; Yoo HJ; Baik SH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM
Cardiovasc Diabetol; 2022 Jan; 21(1):15. PubMed ID: 35101050
[TBL] [Abstract][Full Text] [Related]
34. Diabetes and cardiovascular disease: the role of glycemic control.
Cheng AY; Leiter LA
Curr Diab Rep; 2009 Feb; 9(1):65-72. PubMed ID: 19192427
[TBL] [Abstract][Full Text] [Related]
35. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
Paty BW
Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Neuropathy, Glycemic Control, and Revascularization as Risk Factors for Future Lower Extremity Amputation among Diabetic Patients.
Goldman MP; Corriere MA; Craven T; Davis RP; Sheehan M; Hurie JB; Velazquez G; Williams TK; Chang K; Edwards MS
Ann Vasc Surg; 2021 May; 73():254-263. PubMed ID: 33248240
[TBL] [Abstract][Full Text] [Related]
37. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes?
Zoppini G; Verlato G; Targher G; Casati S; Gusson E; Biasi V; Perrone F; Bonora E; Muggeo M
Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):334-9. PubMed ID: 18571393
[TBL] [Abstract][Full Text] [Related]
38. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial.
Saremi A; Schwenke DC; Bahn G; Ge L; Emanuele N; Reaven PD;
Metabolism; 2015 Feb; 64(2):218-25. PubMed ID: 25456099
[TBL] [Abstract][Full Text] [Related]
39. Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control.
Raghavan S; Josey K; Bahn G; Reda D; Basu S; Berkowitz SA; Emanuele N; Reaven P; Ghosh D
Ann Epidemiol; 2022 Jan; 65():101-108. PubMed ID: 34280545
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
